KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Repligen (RGEN) EBT (2016 - 2025)

Repligen (RGEN) has disclosed EBT for 16 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 62.31% to $19.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.4 million, a 0.16% change, with the full-year FY2025 number at $62.4 million, changed 0.16% from a year prior.
  • EBT was $19.1 million for Q4 2025 at Repligen, up from $17.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $59.8 million in Q2 2022 to a low of -$12.7 million in Q4 2022.
  • A 5-year average of $24.4 million and a median of $18.8 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 136.47% in 2022, then skyrocketed 2619.2% in 2024.
  • Repligen's EBT stood at $34.8 million in 2021, then tumbled by 136.47% to -$12.7 million in 2022, then surged by 114.68% to $1.9 million in 2023, then surged by 2619.2% to $50.7 million in 2024, then crashed by 62.31% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for RGEN's EBT are $19.1 million (Q4 2025), $17.1 million (Q3 2025), and $18.2 million (Q2 2025).